1887
Surveillance and outbreak report Open Access
Like 0

Abstract

The 2014/15 influenza season was the second season of roll-out of a live attenuated influenza vaccine (LAIV) programme for healthy children in England. During this season, besides offering LAIV to all two to four year olds, several areas piloted vaccination of primary (4–11 years) and secondary (11–13 years) age children. Influenza A(H3N2) circulated, with strains genetically and antigenically distinct from the 2014/15 A(H3N2) vaccine strain, followed by a drifted B strain. We assessed the overall and indirect impact of vaccinating school age children, comparing cumulative disease incidence in targeted and non-targeted age groups in vaccine pilot to non-pilot areas. Uptake levels were 56.8% and 49.8% in primary and secondary school pilot areas respectively. In primary school age pilot areas, cumulative primary care influenza-like consultation, emergency department respiratory attendance, respiratory swab positivity, hospitalisation and excess respiratory mortality were consistently lower in targeted and non-targeted age groups, though less for adults and more severe end-points, compared with non-pilot areas. There was no significant reduction for excess all-cause mortality. Little impact was seen in secondary school age pilot only areas compared with non-pilot areas. Vaccination of healthy primary school age children resulted in population-level impact despite circulation of drifted A and B influenza strains.

Loading

Article metrics loading...

/content/10.2807/1560-7917.ES.2015.20.39.30029
2015-10-01
2017-10-19
http://instance.metastore.ingenta.com/content/10.2807/1560-7917.ES.2015.20.39.30029
Loading
Loading full text...

Full text loading...

/deliver/fulltext/eurosurveillance/20/39/eurosurv-20-39-4.html?itemId=/content/10.2807/1560-7917.ES.2015.20.39.30029&mimeType=html&fmt=ahah

References

  1. Baguelin M, Flasche S, Camacho A, Demiris N, Miller E, Edmunds WJ. Assessing optimal target populations for influenza vaccination programmes: an evidence synthesis and modelling study. PLoS Med. 2013;10(10):e1001527.  https://doi.org/10.1371/journal.pmed.1001527  PMID: 24115913 
  2. Grijalva CG, Zhu Y, Simonsen L, Mitchel E, Griffin MR. The population impact of a large school-based influenza vaccination campaign. PLoS ONE. 2010;5(11):e15097.  https://doi.org/10.1371/journal.pone.0015097  PMID: 21209872 
  3. King JC Jr, Cummings GE, Stoddard J, Readmond BX, Magder LS, Stong M, et al. A pilot study of the effectiveness of a school-based influenza vaccination program. Pediatrics. 2005;116(6):e868-73.  https://doi.org/10.1542/peds.2005-1301  PMID: 16322144 
  4. King JC Jr, Lichenstein R, Cummings GE, Magder LS. Impact of influenza vaccination of schoolchildren on medical outcomes among all residents of Maryland. Vaccine. 2010;28(49):7737-42.  https://doi.org/10.1016/j.vaccine.2010.09.064  PMID: 20933566 
  5. Pebody RG, Green HK, Andrews N, Zhao H, Boddington N, Bawa Z, et al. Uptake and impact of a new live attenuated influenza vaccine programme in England: early results of a pilot in primary school-age children, 2013/14 influenza season. Euro Surveill. 2014;19(22):20823.  https://doi.org/10.2807/1560-7917.ES2014.19.22.20823  PMID: 24925457 
  6. Department of Health. Public Health England (PHE). The national flu immunisation programme 2014/15. London: PHE. 28 Apr 2014. Available from: https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/316007/FluImmunisationLetter2014_accessible.pdf
  7. Public Health England (PHE). Surveillance of influenza and other respiratory viruses in the United Kingdom: winter 2014 to 2015. London: PHE. May 2015. Available from: https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/429617/Annualreport_March2015_ver4.pdf
  8. Broberg E, Snacken R, Adlhoch C, Beauté J, Galinska M, Pereyaslov D, et al. WHO European Region and the European Influenza Surveillance Network. Start of the 2014/15 influenza season in Europe: drifted influenza A(H3N2) viruses circulate as dominant subtype. Euro Surveill. 2015;20(4):21023.  https://doi.org/10.2807/1560-7917.ES2015.20.4.21023  PMID: 25655052 
  9. Bolotin S, Pebody R, White PJ, McMenamin J, Perera L, Nguyen-Van-Tam JS, et al. A new sentinel surveillance system for severe influenza in England shows a shift in age distribution of hospitalised cases in the post-pandemic period. PLoS ONE. 2012;7(1):e30279.  https://doi.org/10.1371/journal.pone.0030279  PMID: 22291929 
  10. Public Health England (PHE). Eastern Region Public Health Observatory (Erpho). Acute hospital catchment populations 2009. London: PHE. [Accessed 16 Jun 2015]. Available from: http://www.erpho.org.uk/viewResource.aspx?id=21919
  11. Office for National Statistics. Population Estimates for UK, England and Wales, Scotland and Northern Ireland, Mid-2013 – SUPERSEDED. London: Office for National Statistics. 26 Jun 2014. Available from: http://www.ons.gov.uk/ons/publications/re-reference-tables.html?edition=tcm%3A77-322718
  12. Zhao H, Green H, Lackenby A, Donati M, Ellis J, Thompson C, et al. A new laboratory-based surveillance system (Respiratory DataMart System) for influenza and other respiratory viruses in England: results and experience from 2009 to 2012. Euro Surveill. 2014;19(3):20680.  https://doi.org/10.2807/1560-7917.ES2014.19.3.20680  PMID: 24480060 
  13. Elliot AJ, Hughes HE, Hughes TC, Locker TE, Shannon T, Heyworth J, et al. Establishing an emergency department syndromic surveillance system to support the London 2012 Olympic and Paralympic Games. Emerg Med J. 2012;29(12):954-60.  https://doi.org/10.1136/emermed-2011-200684  PMID: 22366039 
  14. Nielsen J, Mazick A, Andrews N, Detsis M, Fenech TM, Flores VM, et al. Pooling European all-cause mortality: methodology and findings for the seasons 2008/2009 to 2010/2011. Epidemiol Infect. 2013;141(9):1996-2010.  https://doi.org/10.1017/S0950268812002580  PMID: 23182146 
  15. Mazick A, Gergonne B, Nielsen J, Wuillaume F, Virtanen MJ, Fouillet A, et al. Excess mortality among the elderly in 12 European countries, February and March 2012. Euro Surveill. 2012;17(14):20138. PMID: 22516003 
  16. World Health Organization (WHO). International statistical classification of diseases and related health problems. - 10th revision. Geneva: WHO; 2010. Available from: www.who.int/classifications/icd/ICD10Volume2_en_2010.pdf
  17. Regan DG, Hocking JS. Greatest effect of HPV vaccination from school-based programmes. Lancet Infect Dis. 2015;15(5):497-8.  https://doi.org/10.1016/S1473-3099(15)70078-2  PMID: 25744473 
  18. Green HK, Andrews N, Letley L, Sunderland A, White J, Pebody R. Phased introduction of a universal childhood influenza vaccination programme in England: population-level factors predicting variation in national uptake during the first year, 2013/14. Vaccine. 2015;33(22):2620-8.  https://doi.org/10.1016/j.vaccine.2015.03.049  PMID: 25835576 
  19. Tran CH, Sugimoto JD, Pulliam JR, Ryan KA, Myers PD, Castleman JB, et al. School-located influenza vaccination reduces community risk for influenza and influenza-like illness emergency care visits. PLoS ONE. 2014;9(12):e114479.  https://doi.org/10.1371/journal.pone.0114479  PMID: 25489850 
  20. Brousseau N, Green HK, Andrews N, Pryse R, Baguelin M, Sunderland A, et al. Impact of influenza vaccination on respiratory illness rates in children attending private boarding schools in England, 2013-2014: a cohort study. Epidemiol Infect. 2015;Apr 16:1-11.  https://doi.org/10.1017/S0950268815000667  PMID: 25876454 
  21. Pebody RG, Warburton F, Andrews N, Ellis J, von Wissmann B, Robertson C, et al. Effectiveness of seasonal influenza vaccine in preventing laboratory-confirmed influenza in primary care in the United Kingdom: 2014/15 end of season results. Euro Surveill. 2015;20(36):21237.
  22. Nichol KL, Mendelman PM, Mallon KP, Jackson LA, Gorse GJ, Belshe RB, et al. Effectiveness of live, attenuated intranasal influenza virus vaccine in healthy, working adults: a randomized controlled trial. JAMA. 1999;282(2):137-44. https://doi.org/10.1001/jama.282.2.137  PMID: 10411194 
/content/10.2807/1560-7917.ES.2015.20.39.30029
Loading

Data & Media loading...

Comment has been disabled for this content
Submit comment
Close
Comment moderation successfully completed
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error